NEW YORK, July 26, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Zymergen Inc. (NASDAQ: ZY) (“Zymergen”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Ginkgo Bioworks (NYSE: DNA) (“Ginkgo”).
Click here to learn more and participate in the action.
On July 25, 2022, Zymergen announced that it had entered into an agreement to be acquired by Ginkgo in an all-stock deal valued at $265 million. Pursuant to the merger agreement, Zymergen stockholders will receive a fixed exchange ratio of 0.9179 Ginkgo shares for each Zymergen share. The deal is scheduled to close in the first quarter of 2023.
Bragar Eagel & Squire is concerned that Zymergen’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Zymergen’s stockholders.
If you own shares of Zymergen and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato by email at email@example.com or telephone at (646) 860-9157, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.